Cardiac and vascular effects of diltiazem, dobutamine and amrinone, drugs used after myocardial revascularization

Brazilian Journal of Medical and Biological Research

Volumn 37, Issue 6, 2004, Pages 893-900

  Gomez Alvis A ^a   Rebolledo, A ^a   Milesi, V ^a   Raingo, J ^a   Sanz, N ^b   Tommasi, J ^b   Drago, A ^b   Rinaldi, G ^a   Grassi, A ^a  

^a FACULTAD DE CIENCIAS EXACTAS   (Argentina)

^b Casa Hospital San Juan de Dios   (Argentina)

Author keywords

Amrinone; Diltiazem; Dobutamine; Mammary artery; Saphenous vein

Indexed keywords

AMRINONE; DILTIAZEM; DOBUTAMINE; NORADRENALIN; POTASSIUM;

ANIMAL TISSUE; ARTERY CONSTRICTION; ARTICLE; BLOOD VESSEL GRAFT; CARDIOVASCULAR EFFECT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG USE; FEMALE; GRAFT PATENCY; HEART ATRIUM; HEART HEMODYNAMICS; HEART MUSCLE CONTRACTILITY; HEART MUSCLE REVASCULARIZATION; HEART PERFORMANCE; HEART STROKE VOLUME; HUMAN; HUMAN TISSUE; INOTROPISM; ISOLATED ARTERY; MAMMARY ARTERY; MEMBRANE DEPOLARIZATION; NONHUMAN; PERFUSION PRESSURE; POSTOPERATIVE CARE; RAT; SAPHENOUS VEIN; THORACIC AORTA; VASODILATATION;

ANIMALIA;

EID: 3042676836     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2004000600015     Document Type: Article

References (20)

1. Dundore RL, Pagani ED, Bode DC, Bacon ER, Singh B, Lesher GY, Buchholz RA & Silver PJ (1995). Species-dependent pharmacodynamic effects of the selective low Km cyclic AMP phosphodiesterase III inhibitors WIN 8993 and WIN 62005. Journal of Cardiovascular Pharmacology, 25: 14-21.
2. He G-W & Yang Ch-Q (1996). Inhibition of vasoconstriction by phosphodiesterase III inhibitor milrinone in human conduit arteries used as coronary bypass grafts. Journal of Cardiovascular Pharmacology, 28: 208-214.
3. Mori K, Takeuchi S, Moritoki H, Tsuchiya K, Nakaya Y, Matsuoka S & Kuroda Y (1996). Endothelium-dependent relaxation of rat thoracic aorta by amrinone-induced nitric oxide release. European Heart Journal, 17: 308-316.
4. Vroom MB, Pfaffendorf M, van Wezel HB & van Zwieten PA (1996). Effect of phosphodiesterase inhibitors on human arteries in vitro. British Journal of Anaesthesia, 76: 122-129.
5. Sakane T, Ishibashi Y, Shimada T, Takahashi N, Sugamori T, Hirano Y, Ohata S, Inoue SI, Nakamura K & Murakami Y (2000). Impaired vasodilatation response to amrinone in the forearm of patients with congestive heart failure: Role of endothelium-derived nitric oxide. Journal of Cardiovascular Pharmacology, 36: 188-195.
6. Luscher TF (2001). Vascular protection: current possibilities and future perspectives. International Journal of Clinical Practice, 117 (Suppl): 3-6.
7. Grassi AO, Pérez Alzueta AD & Cingolani HE (1977). Effect of isoproterenol on relation between maximal rate of contraction and maximal rate of relaxation. American Journal of Physiology, 233: H404-H409.
8. Vittone L, Grassi AO, Chiappe L, Argel M & Cingolani HE (1981). Relaxing effects of pharmacological interventions increasing cAMP in rat heart. American Journal of Physiology, 240: H441-H447.
9. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC & Stinson EB (1982). Decreased catecholamine sensitivity and beta-receptor density in failing human hearts. New England Journal of Medicine, 307: 205-211.
10. Monrad ES, Baim DS, Smith HS & Lanoue AS (1986). Milrinone, dobutamine and nitroprusside. Comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure. Circulation, 73 (Suppl II): 168-174.
11. Baim DS (1989). Effect of phosphodiesterase inhibition on myocardial oxygen consumption and coronary blood flow. American Journal of Cardiology, 63: 23A-25A.
12. Siostrzonek P, Koreny M, Delle-Karth G, Haumer M, Koller-Strametz J & Heinz G (2000). Milrinone therapy in catecholamine dependent critically ill patients with heart failure. Acta Anaesthesiologica Scandinavica, 44: 403-409.
13. Ludmer PL, Wright RF, Arnold MO, Ganz P, Braunwald E & Colucci WS (1986). Separation of the direct myocardial and vasodilator actions of milrinone administered by an intracoronary infusion technique. Circulation, 73: 130-137.
14. Pagel PS, Hettrick DA & Warltier DC (1993). Amrinone enhances myocardial contractility and improves left ventricular diastolic function in conscious and anesthetized chronically instrumented dogs. Anesthesiology, 79: 753-765.
15. Taira N (1988). Inotropic agents: new positive inotropic agents and their mechanism of action. In: Rand MJ & Raper C (Editors , Pharmacology. Elsevier, Amsterdam, The Netherlands, 477-480.
16. Lawless ST, Zarisky A & Miles M (1991). The acute pharmacokinetics and pharmacodynamics of amrinone in pediatric patients. Journal of Clinical Pharmacology, 31: 800-803.
17. Rinaldi G, Navia D, Vaccarino G, Segura E & Albertal J (2000). Vasodilatadores en arterias radiales humanas aisladas. Medicina, 60: 420-426.
18. Milesi V, Rebolledo A, Ayala Paredes F, Sanz N, Tommasi J, Rinaldi G & Grassi A (1998). Mechanical properties of human saphenous veins from normotensive and hypertensive patients. Annals of Thoracic Surgery, 66: 455-461.
19. Milesi V, Rebolledo A, Gomez-Alvis A, Sanz N, Tommasi J, Drago A, Raingo J, Rinaldi GJ & Grassi de Gende AO (2001). Aspectos estructurales y funcionales de la vena safena humana utilizada como puente aorto-coronario en la cirugla de revascularización miocárdica. Medicina, 61: 481-490.
20. Ichioka Sh, Nakatsuka T, Ohura N, Sato Y & Harii K (2000). Topical application of amrinone (a selective phosphodiesterase III inhibitor) for relief of vasospasm. Journal of Surgical Research, 93: 149-155.